

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Peter DROISCHER et al.

Serial No. 09/963,680

Filed: September 27, 2001

For: 17-METHYLENE STEROIDS, PROCESS FOR THEIR PRODUCTION AND
PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THESE COMPOUNDS

Group Art Unit: 1616

Examiner: QAZI, Sabiha Naim

LETTER TO THE PTO

Via Fax: 571-273-0622
Commissioner for Patents
P O Box 1450
Alexandria, VA 22313-1450

Sir,

Further to a request from the Examiner on the telephone on June 8, 2004, that applicants make a summary statement as to the meaning of the data appearing in tables 1 and 2 of the application, the statements follow.

Table 1 demonstrates that the 5 α -reductase-type 2-activity in genital dermal homogenates is such that the IC₅₀ for the tested compound is 250 nM, which corresponds to a 60% binding to progesterone-receptors (PR) when compared to 100% progesterone.

Table 2 demonstrates that when the dose is 0.1 mg/animal/day, 0 out of 5 tested animals are pregnant, and when the dose is 1.0 mg/animal/day, 5 out of 5 animals are pregnant.

Respectfully submitted,

Csaba Hentz, Reg. No. 50,908
Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410
Attorney Docket No.: JENA-1

Date: June 14, 2004
R:\Milen\14-04\12:39:03 PM (14-Jun-04)